Learn more →
Back to Expert Scholars
research / researchbiliary tract oncology

Jesper B. Andersen

耶斯佩尔·安徒生

PhD

🏢University of Copenhagen, Biotech Research & Innovation Centre (BRIC)(哥本哈根大学生物技术研究与创新中心)🌐Denmark

Professor; Head, Translational Liver Cancer Research Group教授;转化肝癌研究组组长

48
h-index
2
Key Papers
2
Awards
3
Key Contributions

👥Biography 个人简介

Jesper B. Andersen, PhD is a professor at the University of Copenhagen's BRIC whose group is internationally recognized for elucidating the molecular heterogeneity and epigenetic landscape of cholangiocarcinoma (CCA). His laboratory identified several recurrent molecular subtypes of intrahepatic CCA with distinct driver alterations—including FGFR2 fusions and IDH1/2 mutations—and has dissected the stromal and immune microenvironmental features that influence prognosis and treatment response. His work has directly informed the clinical development of FGFR inhibitors and epigenetic therapies in biliary tract cancers.

Share:

🧪Research Fields 研究领域

Cholangiocarcinoma胆管癌
FGFR2 FusionsFGFR2融合
Biliary Tract Cancer胆道肿瘤
Tumor Epigenomics肿瘤表观基因组学
Liver Cancer Biology肝癌生物学

🎓Key Contributions 主要贡献

Molecular Subtyping of Cholangiocarcinoma

Generated comprehensive multi-omic maps of intrahepatic and extrahepatic CCA that revealed actionable molecular subtypes, enabling biomarker-stratified clinical trials and precision therapy approaches for this heterogeneous disease.

Epigenomic Regulation in Biliary Cancers

Characterized DNA methylation and chromatin remodeling landscapes in CCA, identifying epigenetically silenced tumor suppressor genes and proposing epigenetic reprogramming as a therapeutic vulnerability.

FGFR2 Fusion Biology

Defined the functional consequences of FGFR2 gene fusions in CCA cells, demonstrating oncogenic dependency and providing mechanistic rationale for clinical use of selective FGFR inhibitors such as pemigatinib and infigratinib.

Representative Works 代表性著作

[1]

Genomic and Molecular Landscape of Cholangiocarcinoma Identifies Distinct Subtypes

Nature Genetics (2021)

Landmark multi-omic analysis of 492 CCA tumors revealing molecular classification with clinical and therapeutic implications.

[2]

IDH Mutations Remodel the DNA Methylome and Drive Oncogenesis in Intrahepatic Cholangiocarcinoma

Cell Reports (2022)

Demonstrated how IDH1/2 mutations reshape the epigenome in CCA and identified downstream effectors as potential therapeutic targets.

🏆Awards & Recognition 奖项与荣誉

🏆European Research Council Consolidator Grant 2020
🏆Danish Cancer Society Research Award 2019

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 耶斯佩尔·安徒生 的研究动态

Follow Jesper B. Andersen's research updates

留下邮箱,当我们发布与 Jesper B. Andersen(University of Copenhagen, Biotech Research & Innovation Centre (BRIC))相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment